現(xiàn)代脂質(zhì)三聯(lián)治療ppt課件(完整版)
【正文】 es Percent change pared to placebo at 1 year Secondary Prevention in 2531 men with low HDLC amp。 Lipid Metabolism Disorders and CHD。 Lipid Metabolism Disorders and CHD。 15 (3): 23143 LDL Reduction with mg of Cerivastatin 90 80 70 60 50 40 30 20 10 0 ? 30 ? 35 ? 40 ? 45 Cumulative % of respondents LDL Responder Rates with mg LDL % reduction rates in patients aged 60 to 65 years (n = 156) Data on file 0,0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 16,0 18,0 50 40 30 HDL baseline HDL Responder Rates 50 % HDL increase Data on file mg responder rate at 8 weeks 90 80 70 60 50 40 30 20 10 0 ? 10 ? 20 ? 30 ? 40 ? 50 TG responder rates for mg TG % reduction rates from baseline ? 300 mg/dl at 8 weeks ( n = 43) Cumulative % of respondents Data on file 20 10 0 30 40 5 placebo Baseline triglycerides 150 mg/dl 150250 mg/dl 250 mg/dl 10 35 25 15 5 TG Reduction STEIN E et al. Atherosclerosis 1999。85, 1: 37 “ Patients in the placebo group with triglyceride levels of ? 200 mg/dl and an LDL/HDL ratio of ? had by far the highest incidence of cardiac events” Gerd Assmann, Lipid Metabolism Disorders and Coronary Heart Disease, MMV Medizin Verlag, 1993 The Lipid Triad Expert Comments PROCAM “The greatest difference, in relative terms, between the groups with and without major coronary events was seen in the LDL/HDLratio” Assmann G, Cullen P and Schulte H。 Lipid Metabolism Disorders and CHD。 79: 8 15. HDL C [mg / dl] 65 55 45 35 LDL Cholesterol mg / dl LDL Cholesterol mg / dl 12 10 8 6 4 2 0 100 130 160 190 0 1 2 3 Framingham Heart Study CAD risk as a function of LDLC and HDLC in men (50 to 70 y) CASTELLI WP. Am J Cardiol 1998。 LDLC showed a 22% reduction in bined fatal and nonfatal MI HDL Cholesterol as Risk Factor for CHD LRC CPPT (Placebo) MRFIT (usual care) Incidence rate of CHD Incidence rate of CHD 12 10 8 6 4 2 0 100 130 160 190 GORDON DJ et al. Circulation 1989。
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1